
VLS-1272 is an orally bioavailable, мощный, ATP non-competitive, microtubule-dependent, and highly селективный ингибитор of KIF18A. VLS-1272 is селективный for KIF18A over other kinesins, with no inhibition of KIF11/Eg5, KIF18B, or KIFC1 at 100 µM, and IC50 of 280 nM against KIF19. VLS-1272 treatment results in mitotic defects leading to substantial, dose-dependent inhibition of tumor growth.
VLS-1272 is an orally bioavailable, potent, ATP non-competitive, microtubule-dependent, and highly selective inhibitor of KIF18A. VLS-1272 is selective for KIF18A over other kinesins, with no inhibition of KIF11/Eg5, KIF18B, or KIFC1 at 100 µM, and IC50 of 280 nM against KIF19. VLS-1272 treatment results in mitotic defects leading to substantial, dose-dependent inhibition of tumor growth.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.